In order to meet our objective to promote leukodystrophy medical research we work collaboratively with a variety of stakeholders with an interest in leukodystrophy, including pharmaceutical companies and healthcare industries that make a profit.

Read our policy on Working with Industry here.

As part of this policy we are committed to:

  • transparency about the income we receive from pharmaceutical companies;
  • adherence to the ABPI Code of Practice for the Pharmaceutical Industry or other relevant overseas codes, legislation and guidance
  • adherence to the ABPI Guide for charities working with industry
  • independence and impartiality – Alex TLC activities and information are not influenced by the acceptance of industry sponsorship

For further details of our income and expenditure please see our annual accounts for the financial year ending 30 June 2025: Alex TLC annual accounts

The table below outlines the individual companies and amounts received for the last two financial years to 30 June 2024 and 30 June 2025:

Company2024/252023/24
Minoryx36,900.00
Ionis17,000.0010,000.00
Orchard10,550.00
Vigil13,700.0010,000.00
BridgeBio18,232.40
Forge Biologics1,988.00
Neuraxpharm5,400.00
SynaptixBio Ltd1,509.52
Swanbio Therapeutics5,000.00
TOTAL105,279.9225,000.00